3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precancerous Conditions
3
Breast Neoplasms
3
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Adenomatous Polyposis Coli
2
Tobacco Use Disorder
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Intraductal Neoplasms
1
Pain
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hypertension
1
Desmoid Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn